|
1
|
Satoh K, Fukumoto Y and Shimokawa H:
Rho-kinase: Important new therapeutic target in cardiovascular
diseases. Am J Physiol Heart Circ Physiol. 301:H287–H296. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hahmann C and Schroeter T: Rho-kinase
inhibitors as therapeutics: From pan inhibition to isoform
selectivity. Cell Mol Life Sci. 67:171–177. 2010. View Article : Google Scholar
|
|
3
|
Olson MF: Applications for ROCK kinase
inhibition. Curr Opin Cell Biol. 20:242–248. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ming D, Yan BP, Liao JK, Lam YY, Yip GW
and Yu CM: Rho-kinase inhibition: A novel therapeutic target for
the treatment of cardiovascular diseases. Drug Discov Today.
15:622–629. 2010. View Article : Google Scholar
|
|
5
|
Budzyn K, Marley PD and Sobey CG:
Targeting Rho and Rho-kinase in the treatment of cardiovascular
disease. Trends Pharmacol Sci. 27:97–104. 2006. View Article : Google Scholar
|
|
6
|
Shimokawa H and Rashid M: Development of
Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol
Sci. 28:296–302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kushiyama T, Oda T, Yamamoto K, Higashi K,
Watanabe A, Takechi H, Uchida T, Oshima N, Sakurai Y, Miura S and
Kumagai H: Protective effects of Rho kinase inhibitor fasudil on
rats with chronic kidney disease. Am J Physiol Renal Physiol.
304:F1325–F1334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nishikimi T, Koshikawa S, Ishikawa Y,
Akimoto K, Inaba C, Ishimura K, Ono H and Matsuoka H: Inhibition of
Rho-kinase attenuates nephrosclerosis and improves survival in
salt-loaded spontaneously hypertensive stroke-prone rats. J
Hypertens. 25:1053–1063. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kanda T, Wakino S, Hayashi K, Homma K,
Ozawa Y and Saruta T: Effect of fasudil on Rho-kinase and
nephropathy in subtotally nephrectomized spontaneously hypertensive
rats. Kidney Int. 64:2009–2019. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xie X, Peng J, Chang X, Huang K, Huang J,
Wang S, Shen X, Liu P and Huang H: Activation of RhoA/ROCK
regulates NF-κB signaling pathway in experimental diabetic
nephropathy. Mol Cell Endocrinol. 369:86–97. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou H, Li YJ, Wang M, Zhang LH, Guo BY,
Zhao ZS, Meng FL, Deng YG and Wang RY: Involvement of RhoA/ROCK in
myocardial fibrosis in a rat model of type 2 diabetes. Acta
Pharmacol Sin. 32:999–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li Y, Zhu W, Tao J, Xin P, Liu M, Li J and
Wei M: Fasudil protect the heart against ischemia-reperfusion
injury by attenuating endoplasmic reticulum stress and modulating
SERCA activity: The differential role for PI3K/Akt and JAK2/STAT3
signaling pathways. PLoS One. 7:e481152012. View Article : Google Scholar
|
|
13
|
Kentrup D, Reuter S, Schnöckel U, Grabner
A, Edemir B, Pavenstädt H, Schober O, Schäfers M, Schlatter E and
Büssemaker E: Hydroxyfasudil-mediated inhibition of ROCK1 and ROCK2
improves kidney function in rat renal acute ischemia-reperfusion
injury. PLoS One. 6:e264192011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matoba K, Kawanami D, Okada R, Tsukamoto
M, Kinoshita J, Ito T, Ishizawa S, Kanazawa Y, Yokota T, Murai N,
et al: Rho-kinase inhibition privents the progression of diabetic
nephropathy by downregulating hypoxia-inducible factor 1α. Kidney
Int. 84:545–554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Diah S, Zhang GX, Nagai Y, Zhang W, Gang
L, Kimura S, Hamid MR, Tamiya T, Nishiyama A and Hitomi H:
Aldosterone induced mypfibroblastic transdifferentiation and
collagen gene expression through the Rho-kinase dependent signaling
pathway in rat mesangial cells. Exp Cell Res. 314:3654–3662. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei J, Li Z, Ma C, Zhan F, Wu W, Han H,
Huang Y, Li W, Chen D and Peng Y: Rho kinase pathway is likely
responsible for the profibrotic actions of aldosterone in renal
epithelial cells via inducing epithelial-mesenchymal transition and
extracellular matrix excretion. Cell Biol Int. 37:725–730. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Manickam N, Patel M, Griendling KK, Gorin
Y and Barnes JL: RhoA/Rho kinase mediates TGF-β1-induced kidney
myofi-broblast activation through Poldip2/Nox4-derived reactive
oxygen species. Am J Physiol Renal Physiol. 307:F159–F171. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nagatoya K, Moriyama T, Kawada N, Takeji
M, Oseto S, Murozono T, Ando A, Imai E and Hori M: Y-27632 prevents
tubulointerstitial fibrosis in mouse kidneys with unilateral
ureteral obstruction. Kidney Int. 61:1684–1695. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Satoh S, Yamaguchi T, Hitomi A, Sato N,
Shiraiwa K, Ikegaki I, Asano T and Shimokawa H: Fasudil attenuates
interstitial fibrosis in rat kidneys with unilateral ureteral
obstruction. Eur J Pharmacol. 455:169–174. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Takeda Y, Nishikimi T, Akimono K, Matsuoka
H and Ishimitsu T: Benefical effects of a combination of Rho-kinase
inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced
by unilateral ureteral obstruction. Hypertens Res. 33:965–973.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kakimoto T, Kimata H, Iwasaki S, Fukunari
A and Utsumi H: Automated recognition and quantification of
pancreatic islets in Zucker diabetic fatty rats treated with
exendin-4. J Endocrinol. 216:13–20. 2013. View Article : Google Scholar
|
|
22
|
Woessner JF Jr: The determination of
hydroxyproline in tissue and protein samples containing small
proportions of this imino acid. Arch Biochem Biophys. 93:440–447.
1961. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kivirikko KI, Laitinen O and Prockop DJ:
Modifications of a specific assay for hydroxyproline in urine. Anal
Biochem. 19:249–255. 1967. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chevalier RL, Forbes MS and Thornhill BA:
Ureteral obstruction as a model of renal interstitial fibrosis and
obstructive nephropathy. Kidney Int. 75:1145–1152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chevalier RL: Obstructive nephropathy:
Towards biomarker discovery and gene therapy. Nat Clin Pract
Nephrol. 2:157–168. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen B, Liu X, Fan Y and Qiu J:
Macrophages regulate renal fibrosis through modulating TGFβ
superfamily signaling. Inflammation. 37:2076–2084. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang HC, Zuo Y and Fogo AB: Models of
chronic kidney disease. Drug Discov Today Dis Models. 7:13–19.
2010. View Article : Google Scholar
|
|
28
|
Löpez-Novoa JM, Martinez-Salgado C,
Rodriguez-Peña AB and López-Hernández FJ: Common pathophysiological
mechanisms of chronic kidney disease. Therapeutic perspectives
Pharmacol Ther. 128:61–81. 2010. View Article : Google Scholar
|
|
29
|
Truong LD, Gaber L and Eknoyan G:
Obstructive uropathy. Contrib Nephrol. 169:311–326. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Eddy AA, López-Guisa JM, Okamura DM and
Yamaguchi I: Investigating mechanizes of chronic kidney disease in
mouse models. Pediatr Nephrol. 27:1233–1247. 2012. View Article : Google Scholar
|
|
31
|
Fu P, Liu F, Su S, Wang W, Huang XR,
Entman ML, Schwartz RJ, Wei L and Lan HY: Signaling mechanism of
renal fibrosis in unilateral ureteral obstructive kidney disease in
ROCK1 knockout mice. J Am Soc Nephrol. 17:3105–3114. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ballhause TM, Soldati R and Mertens PR:
Sources of myofibroblats in kidney fibrosis: All answers are
correct, however to different extent! Int Urol Nephrol. 46:659–664.
2014. View Article : Google Scholar
|
|
33
|
Duffield JS: Cellular and molecular
mechanisms in kidney fibrosis. J Clin Invest. 124:2299–2306. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pan SY, Chang YT and Lin SL: Microvascular
pericytes in healthy and diseased kidneys. Int J Nephrol Renovascul
Disease. 7:39–48. 2014.
|
|
35
|
LeBleu VS, Taduri G, O'Connell J, Teng Y,
Cooke VG, Wada C, Sugimoto H and Kalluri R: Origin and function of
myofibroblasts in kidney fibrosis. Nat Med. 19:1047–1053. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jang HS, Kim JI, Jung KJ, Kim J, Han KH
and Park KM: Bone marrow-derived cells play a major role in kidney
fibrosis via proliferation and differentiation in the infiltrated
site. Biochim Biophys Acta. 1832:817–825. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qin J, Xie YY, Huang L, Yuan QJ, Mei WJ,
Yuan XN, Hu GY, Cheng GJ, Tao LJ and Peng ZZ: Fluorofenidone
inhibits nicotinamide adeninedinucleotide phosphate oxidase via
PI3K/Akt pathway in the pathogenesis of renal interstitial
fibrosis. Nephrology (Carlton). 18:690–699. 2013.
|
|
38
|
Gu L, Gao Q, Ni L, Wang M and Shen F:
Fasudil inhibits epithelialmyofibroblast transdifferentiation of
human renal tubular epithelial HK-2 cells induced by high glucose.
Chem Pharm Bull (Tokyo). 61:688–694. 2013. View Article : Google Scholar
|
|
39
|
Gande MT, Pèrez-Barriocanal F and
López-Novoa JM: Role of inflammation in tubule-interstitial damage
associated to obstructive nephropathy. J Inflamm (Lond). 7:192010.
View Article : Google Scholar
|
|
40
|
Wang Y and Harris DC: Macrophages in renal
disease. J Am Soc Nephrol. 22:21–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chung AC and Lan HY: Chemokines in renal
injury. J Am Soc Nephrol. 22:802–809. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu N, Tolbert E, Pang M, Ponnusamy MI,
Yan H and Zhuang S: Suramin inhibits renal fibrosis in chronic
kidney disease. J Am Soc Nephrol. 22:1064–1075. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pang M, Ma L, Gong R, Tolbert E, Mao H,
Ponnusamy M, Chin YE, Yan H, Dworkin LD and Zhuang S; A novel STAT3
inhibitor: S31–201. attenuates renal interstitial fibroblast
activation and interstitial fibrosis in obstructive nephropathy.
Kidney Int. 78:257–268. 2010. View Article : Google Scholar
|
|
44
|
Meng XM, Huang XR, Xiao J, Chen HY, Zhong
X, Chung AC and Lan HY: Diverse roles of TGF-β receptor II in renal
fibrosis and inflammation in vivo and in vitro. J Pathol.
227:175–188. 2012. View Article : Google Scholar
|
|
45
|
Anders HJ and Ryu M: Renal
microenvironments and macrophage phenotypes determine progression
or resolution of renal inflammation and fibrosis. Kidney Int.
80:915–925. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ricardo SD, van Goor H and Eddy AA:
Macrophage diversity in renal injury and repair. J Clin Invest.
118:3522–3530. 2008. View Article : Google Scholar : PubMed/NCBI
|
